A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• CiomborKKBerlinJTargeting metastatic colorectal cancer – present and emerging treatment optionsPharmgenomics Pers Med2014713714425045279
   PubMedGoogle Scholar
• CunninghamDPyrhonenSJamesRDRandomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerLancet1998352141314189807987
   PubMed Web of Science ®Google Scholar
• RougierPVan CutsemEBajettaERandomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerLancet1998352140714129807986
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C StudyJ Clin Oncol2007254779478617947725
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerNew Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol2010284706471320921462
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHLangICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol2011292011201921502544
   PubMed Web of Science ®Google Scholar
• MacarullaTSauriTTaberneroJEvaluation of aflibercept in the treatment of metastatic colorectal cancerExpert Opin Biol Ther2014141493150525152076
   PubMed Web of Science ®Google Scholar
• SastreJArgilesGBenavidesMClinical management of regorafenib in the treatment of patients with advanced colorectal cancerClin Transl Oncol2014
   Web of Science ®Google Scholar
• TimarJThe clinical relevance of KRAS gene mutation in non-small-cell lung cancerCurr Opin Oncol20142613814424463346
   PubMed Web of Science ®Google Scholar
• BosJLRas oncogenes in human cancer: a reviewCancer Res198949468246892547513
   PubMed Web of Science ®Google Scholar
• AndreyevHJNormanARCunninghamDKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBr J Cancer20018569269611531254
   PubMed Web of Science ®Google Scholar
• EstellerMGonzalezSRisquesRAK-ras and p16 aberrations confer poor prognosis in human colorectal cancerJ Clin Oncol20011929930411208819
   PubMed Web of Science ®Google Scholar
• ImamuraYLochheadPYamauchiMAnalyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature reviewMol Cancer20141313524885062
   PubMed Web of Science ®Google Scholar
• CohnALShumakerGCKhandelwalPAn open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancerClin Colorectal Cancer20111017117721855038
   PubMed Web of Science ®Google Scholar
• MitchellEPPiperdiBLacoutureMEThe efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS statusClin Colorectal Cancer20111033333922000810
   PubMed Web of Science ®Google Scholar
• HockingCMPriceTJPanitumumab in the management of patients with KRAS wild-type metastatic colorectal cancerTherap Adv Gastroenterol201472037
   PubMed Web of Science ®Google Scholar
• KohneCHHofheinzRMineurLFirst-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerJ Cancer Res Clin Oncol2012138657221960318
   PubMed Web of Science ®Google Scholar
• BerlinJPoseyJTchekmedyianSPanitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancerClin Colorectal Cancer2007642743217531105
   PubMed Web of Science ®Google Scholar
• RakJYuJLKerbelRSCoomberBLWhat do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?Cancer Res2002621931193411929804
   PubMed Web of Science ®Google Scholar
• MizukamiYKohgoYChungDCHypoxia inducible factor-1 independent pathways in tumor angiogenesisClin Cancer Res2007135670567417908955
   PubMed Web of Science ®Google Scholar
• HeinemannVHoffPMBevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancerOncology20107911812821088438
   PubMed Web of Science ®Google Scholar
• HurwitzHIYiJInceWNovotnyWFRosenOThe clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancerOncologist200914222819144677
   PubMed Web of Science ®Google Scholar
• XieSHanGFanZHeLXuWQinZSafety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancerMed Oncol2014313524915899
   PubMed Web of Science ®Google Scholar
• LiangHLHuAPLiSLLiuJYCombining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancerMed Oncol20143197624793617
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
   PubMed Web of Science ®Google Scholar
• FuchsCSMooreMRHarkerGVillaLRinaldiDHechtJRPhase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancerJ Clin Oncol20032180781412610178
   PubMed Web of Science ®Google Scholar
• MuroKBokuNShimadaYIrinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)Lancet Oncol20101185386020708966
   PubMed Web of Science ®Google Scholar